Literature DB >> 9031993

The effect of clozapine on the course of illness in chronic schizophrenia: focus on treatment outcome in out-patients.

G Joffe1, E Venäläinen, J Tupala, O Hiltunen, K Wahlbeck, R Gädeke, R Rimon.   

Abstract

Forty-eight consecutive schizophrenic patients treated with clozapine (mean daily dose 436 mg) for at least 1 year (mean 7.6, range 2.2-14.8 years) were studied retrospectively. The most favourable changes in the course of illness were observed in 39 out-patients, whose duration of hospitalization per year continuously and significantly declined after the introduction of clozapine. The out-patients who continued with clozapine treatment for more than 10 years (n = 8) did not need hospitalization at all during the last year of the observation period. The improvement in social functioning in the out-patient group correlated positively with the duration of clozapine medication (r = 0.384, p = 0.016) and with the duration of hospitalization (r = 0.372, p = 0.020) after introduction of clozapine. Out-patients with disorganized schizophrenia (later called hebephrenic according to the Finish version of DSM-III) showed more noticeable clinical (U = 226, p = 0.032) and social (U = 233, p = 0.024) improvements than non-hebephrenic patients. There appears to be a subgroup of hebephrenic patients who benefit from clozapine more than patients with other types of schizophrenia.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9031993     DOI: 10.1097/00004850-199612000-00008

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  4 in total

1.  Mutant mouse models: genotype-phenotype relationships to negative symptoms in schizophrenia.

Authors:  Colm M P O'Tuathaigh; Brian P Kirby; Paula M Moran; John L Waddington
Journal:  Schizophr Bull       Date:  2009-11-24       Impact factor: 9.306

2.  Chronic low dose risperidone and clozapine alleviate positive but not negative symptoms in the rat neonatal ventral hippocampal lesion model of schizophrenia.

Authors:  Lynne E Rueter; Michael E Ballard; Kelly B Gallagher; Ana Maria Basso; Peter Curzon; Kathy L Kohlhaas
Journal:  Psychopharmacology (Berl)       Date:  2004-06-04       Impact factor: 4.530

Review 3.  Clozapine versus typical neuroleptic medication for schizophrenia.

Authors:  Adib Essali; Nahla Al-Haj Haasan; Chunbo Li; John Rathbone
Journal:  Cochrane Database Syst Rev       Date:  2009-01-21

4.  Milnacipran: in fibromyalgia.

Authors:  Claudine M Chwieduk; Paul L McCormack
Journal:  Drugs       Date:  2010       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.